Peter L Anderson1, J Gerardo García-Lerma, Walid Heneine. 1. aDepartment of Pharmaceutical Sciences, University of Colorado Anschutz Medical Campus, Aurora, Colorado bLaboratory Branch, Division of HIV/AIDS Prevention, Centers for Disease Control and Prevention, Atlanta, Georgia, USA.
Abstract
PURPOSE OF REVIEW: To discuss nondaily preexposure prophylaxis (PrEP) modalities that may provide advantages compared with daily PrEP in cost and cumulative toxicity, but may have lower adherence forgiveness. RECENT FINDINGS: Animal models have informed our understanding of early viral transmission events, which help guide event-driven PrEP dosing strategies. These models indicate early establishment of viral replication in rectal or cervicovaginal tissues, so event-driven PrEP should rapidly deliver high mucosal drug concentrations within hours of the potential exposure event. Macaque models have demonstrated the high biological efficacy for event-driven dosing of oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) against both vaginal and rectal virus transmission. In humans, the IPERGAY study demonstrated 86% efficacy for event-driven oral TDF/FTC dosing among men who have sex with men (MSM), while no similar efficacy data are available on women or heterosexual men. The HPTN 067 study showed that certain MSM populations adhere well to nondaily PrEP, whereas other populations of women adhere more poorly to nondaily versus daily regimens. Pharmacokinetic studies following oral TDF/FTC dosing in humans indicate that TFV-diphosphate (the active form of TFV) accumulates to higher concentrations in rectal versus cervicovaginal tissue, but nonadherence in trials complicates the interpretation of differential mucosal drug concentrations. SUMMARY: Event-driven dosing for TFV-based PrEP has promise for HIV prevention in MSM. Future research of event-driven PrEP in women and heterosexual men should be guided by a better understanding of the importance of mucosal drug concentrations for PrEP efficacy and its sensitivity to adherence.
PURPOSE OF REVIEW: To discuss nondaily preexposure prophylaxis (PrEP) modalities that may provide advantages compared with daily PrEP in cost and cumulative toxicity, but may have lower adherence forgiveness. RECENT FINDINGS: Animal models have informed our understanding of early viral transmission events, which help guide event-driven PrEP dosing strategies. These models indicate early establishment of viral replication in rectal or cervicovaginal tissues, so event-driven PrEP should rapidly deliver high mucosal drug concentrations within hours of the potential exposure event. Macaque models have demonstrated the high biological efficacy for event-driven dosing of oral tenofovir disoproxil fumarate (TDF) and emtricitabine (FTC) against both vaginal and rectal virus transmission. In humans, the IPERGAY study demonstrated 86% efficacy for event-driven oral TDF/FTC dosing among men who have sex with men (MSM), while no similar efficacy data are available on women or heterosexual men. The HPTN 067 study showed that certain MSM populations adhere well to nondaily PrEP, whereas other populations of women adhere more poorly to nondaily versus daily regimens. Pharmacokinetic studies following oral TDF/FTC dosing in humans indicate that TFV-diphosphate (the active form of TFV) accumulates to higher concentrations in rectal versus cervicovaginal tissue, but nonadherence in trials complicates the interpretation of differential mucosal drug concentrations. SUMMARY: Event-driven dosing for TFV-based PrEP has promise for HIV prevention in MSM. Future research of event-driven PrEP in women and heterosexual men should be guided by a better understanding of the importance of mucosal drug concentrations for PrEP efficacy and its sensitivity to adherence.
Authors: Christopher J Miller; Qingsheng Li; Kristina Abel; Eun-Young Kim; Zhong-Min Ma; Stephen Wietgrefe; Lisa La Franco-Scheuch; Lara Compton; Lijie Duan; Marta Dykhuizen Shore; Mary Zupancic; Marc Busch; John Carlis; Steven Wolinsky; Steven Wolinksy; Ashley T Haase Journal: J Virol Date: 2005-07 Impact factor: 5.103
Authors: Koen K A Van Rompay; Brian P Kearney; Jonathan J Sexton; Roxana Colón; Jonathan R Lawson; Emily J Blackwood; William A Lee; Norbert Bischofberger; Marta L Marthas Journal: J Acquir Immune Defic Syndr Date: 2006-09 Impact factor: 3.731
Authors: Caryn N Kim; Debra R Adams; Sheila Bashirian; Sal Butera; Thomas M Folks; Ron A Otten Journal: J Med Primatol Date: 2006-08 Impact factor: 0.667
Authors: C C Tsai; P Emau; K E Follis; T W Beck; R E Benveniste; N Bischofberger; J D Lifson; W R Morton Journal: J Virol Date: 1998-05 Impact factor: 5.103
Authors: Qingsheng Li; Jacob D Estes; Patrick M Schlievert; Lijie Duan; Amanda J Brosnahan; Peter J Southern; Cavan S Reilly; Marnie L Peterson; Nancy Schultz-Darken; Kevin G Brunner; Karla R Nephew; Stefan Pambuccian; Jeffrey D Lifson; John V Carlis; Ashley T Haase Journal: Nature Date: 2009-03-04 Impact factor: 49.962
Authors: K K Van Rompay; C J Berardi; N L Aguirre; N Bischofberger; P S Lietman; N C Pedersen; M L Marthas Journal: AIDS Date: 1998-06-18 Impact factor: 4.177
Authors: J Gerardo García-Lerma; Ron A Otten; Shoukat H Qari; Eddie Jackson; Mian-Er Cong; Silvina Masciotra; Wei Luo; Caryn Kim; Debra R Adams; Michael Monsour; Jonathan Lipscomb; Jeffrey A Johnson; David Delinsky; Raymond F Schinazi; Robert Janssen; Thomas M Folks; Walid Heneine Journal: PLoS Med Date: 2008-02 Impact factor: 11.069
Authors: Sharon M Seifert; Xinhui Chen; Amie L Meditz; Jose R Castillo-Mancilla; Edward M Gardner; Julie A Predhomme; Carolyn Clayton; Gregory Austin; Brent E Palmer; Jia-Hua Zheng; Brandon Klein; Becky J Kerr; L Anthony Guida; Caitlin Rower; Joseph E Rower; Jennifer J Kiser; Lane R Bushman; Samantha MaWhinney; Peter L Anderson Journal: AIDS Res Hum Retroviruses Date: 2016-09-19 Impact factor: 2.205
Authors: Stephanie N Liu; Brandon T Gufford; Jessica Bo Li Lu; Lane R Bushman; Peter L Anderson; Richard F Bergstrom; Zeruesenay Desta; Samir K Gupta Journal: Clin Pharmacol Ther Date: 2019-12-31 Impact factor: 6.875
Authors: Fernanda P Pons-Faudoa; Antons Sizovs; Kathryn A Shelton; Zoha Momin; Jean A Niles; Lane R Bushman; Jiaqiong Xu; Corrine Ying Xuan Chua; Joan E Nichols; Sandra Demaria; Michael M Ittmann; Trevor Hawkins; James F Rooney; Mark A Marzinke; Jason T Kimata; Peter L Anderson; Pramod N Nehete; Roberto C Arduino; Mauro Ferrari; K Jagannadha Sastry; Alessandro Grattoni Journal: Adv Ther (Weinh) Date: 2020-12-16
Authors: Whitney C Sewell; Victoria E Powell; Kenneth H Mayer; Aileen Ochoa; Douglas S Krakower; Julia L Marcus Journal: J Acquir Immune Defic Syndr Date: 2020-06-01 Impact factor: 3.771